Artiva Biotherapeutics (ARTV) Q2 2026 earnings summary

Executive summary

• AlloNK advanced in clinical trials for refractory RA, Sjögren's disease, and systemic sclerosis, with positive initial data and FDA alignment on a registrational trial design for RA.

• Over 70 autoimmune patients treated with AlloNK across global trials; FDA granted RMAT and Fast Track designations for AlloNK in RA, including in combination with rituximab.

• Clinical data at EULAR 2026 reinforced AlloNK's potential for deep B-cell depletion and meaningful clinical activity, with a favorable safety profile for outpatient use.

• No cytokine release syndrome or serious adverse events related to AlloNK reported; efficacy data show over 50% ACR50 response at six months in refractory RA patients.

• Appointment of Diego Miralles, M.D., as president and head of R&D, bringing over 20 years of industry experience.

Financial highlights

• Net loss of $25.0 million for Q2 2026, compared to $21.3 million in Q2 2025; net loss of $48.5 million for the six months ended June 30, 2026.

• Research and development expenses increased to $21.9 million in Q2 2026 from $17.9 million in Q2 2025, driven by AlloNK clinical trial costs.

• Cash, cash equivalents, and investments totaled $349.4 million as of June 30, 2026, up from $108.0 million at year-end 2025, following a $300 million public offering in May 2026.

• General and administrative expenses were $5.0 million for Q2 2026, nearly flat year-over-year.

• Other income, net, was $1.9 million for Q2 2026, up from $1.6 million in Q2 2025.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2029; continued significant losses anticipated as clinical programs advance.

• Phase 3 registrational trial for AlloNK in refractory RA to initiate in H2 2026, targeting approximately 150 patients, with primary efficacy data expected in H2 2028 and potential BLA submission in 2029.